Naijiang Liu

Naijiang Liu

Auto-generated profile, based on publicly available information

Naijiang Liu

Translational Research Center, College of Dentistry, New York University, New York, NY 10010, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2025 in Nature
Verified
Journal Article
Open access
PDF file
EBErez N. Baruch
Erez N. Baruch
FGFrederico Omar Gleber-Netto
Frederico Omar Gleber-Netto
PNPriyadharsini Nagarajan
Priyadharsini Nagarajan
XRXiayu Rao
Xiayu Rao
SAShamima Akhter
Shamima Akhter
Moran AmitMoran Amit
Moran Amit
Perineural invasion (PNI) is a well-established factor of poor prognosis in multiple cancer types1, yet its mechanism remains unclear. Here we provide clinical and mechanistic insights into the role of PNI and cancer-induced nerve injury (CINI) in resistance to anti-PD-1 therapy. Our study demonstrates that PNI and CINI of tumour-associated nerves are associated with poor response to anti-PD-1 therapy among patients with cutaneous squamous cell carcinoma, melanoma and gastric cancer. Electron microscopy and electrical conduction analyses reveal that cancer cells degrade the nerve fibre myelin sheets. The injured neurons respond by autonomously initiating IL-6- and type I interferon-mediated inflammation to promote nerve healing and regeneration. As the tumour grows, the CINI burden increases, and its associated inflammation becomes chronic and skews the general immune tone within the tumour microenvironment into a suppressive and exhaustive state. The CINI-driven anti-PD-1 resistance can be reversed by targeting multiple steps in the CINI signalling process: denervating the tumour, conditional knockout of the transcription factor mediating the injury signal within neurons (Atf3), knockout of interferon-α receptor signalling (Ifnar1−/−) or by combining anti-PD-1 and anti-IL-6-receptor blockade. Our findings demonstrate the direct immunoregulatory roles of CINI and its therapeutic potential.

27 January 2026 in Science Signaling
Verified
Journal Article
Closed access
NLNaijiang Liu
Naijiang Liu
XSXiaojie Shi
Xiaojie Shi
SCShao-Rui Chen
Shao-Rui Chen
HCHong Chen
Hong Chen
MSMaria Daniela Santi
Maria Daniela Santi
YYYi Ye
Yi Ye
Pain associated with oral cancer is debilitating. Opioids are the gold standard for cancer pain management, but tolerance and side effects limit their use. Epidermal growth factor receptor (EGFR) signaling is commonly amplified in oral tumors. Here, we found that EGFR activation contributed to both oral cancer pain and opioid tolerance by sensitizing trigeminal ganglion (TG) cells, the main sensory neurons innervating the face and mouth. EGFR ligands were secreted by oral squamous cell carcinoma (OSCC) cells and by peripheral glial cells cocultured with OSCC cells. In human OSCC and an orthotopic mouse model, EGFR was abundant in tumor-innervating TG nerves. Oral cancer pain and opioid tolerance in the mice were increased by EGFR ligands and reduced by EGFR inhibitors. In mice, the abundance of glutamate-type NMDA receptors (NMDARs) was also increased in both the TG and the brainstem. Upon activation by ligands or OSCC cell supernatant, EGFR phosphorylated the NMDAR subunit GluN2B, which increased electrical currents and sensitized pre- and postsynaptic NMDARs in the brainstem. This sensitization was also seen in the brainstems of mice receiving chronic morphine treatment and was mitigated by EGFR blockade. These findings suggest that EGFR-targeted cancer therapeutics may be repurposed to manage cancer pain and reduce opioid tolerance in patients with OSCC.

22 December 2025 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
ZGZhiting Gong
Zhiting Gong
MZMorgan Zhang
Morgan Zhang
NLNaijiang Liu
Naijiang Liu
KAKesava Asam
Kesava Asam
Stefano MartellucciStefano Martellucci
Stefano Martellucci
YYYi Ye
Yi Ye
Orofacial pain, affecting 10–15% of adults, is a prevalent form of chronic pain that remains a major clinical challenge. The Schwann cell involvement